{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:04:34Z","timestamp":1791849874736,"version":"4.3.4"},"reference-count":282,"publisher":"Elsevier","isbn-type":[{"value":"9780323899390","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN-2017WXR7ZT"],"award-info":[{"award-number":["PRIN-2017WXR7ZT"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.ircmb.2021.09.001","type":"book-chapter","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:30:20Z","timestamp":1635420620000},"page":"1-69","source":"Crossref","is-referenced-by-count":22,"title":["Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0010","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2019.8281","article-title":"Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study","volume":"11","author":"Accurso","year":"2019","journal-title":"Hematol. Rep."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0015","article-title":"Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-\u03b2","volume":"3","author":"Agarwal","year":"2016","journal-title":"Stem Cell investig."},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0020","first-page":"4204","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis (N= 2233)","volume":"130","author":"Al-Ali","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0025","first-page":"215","article-title":"KRT-232, A first-in-class, murine double minute 2 inhibitor, for myelofibrosis relapsed or refractory to janus-associated kinase inhibitor treatment","volume":"4","author":"Al-Ali","year":"2020","journal-title":"Hemasphere."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","author":"Al-Ali","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0040","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0045","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3324\/haematol.2016.146654","article-title":"Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation","volume":"101","author":"Alvarez-Larr\u00e1n","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.13047","article-title":"The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera","volume":"167","author":"Ancochea","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/bs.ircmb.2021.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1582-4934.2001.tb00140.x","article-title":"Abnormalities of platelet aggregation in chronic myeloproliferative disorders","volume":"5","author":"Avram","year":"2001","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0085","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/leu.2016.47","article-title":"Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin","volume":"30","author":"Balligand","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0095","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/bloodadvances.2020003291","article-title":"Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs","volume":"5","author":"Balliu","year":"2021","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/bs.ircmb.2021.09.001_bb0100","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.001_bb0105","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0110","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"13","key":"10.1016\/bs.ircmb.2021.09.001_bb0115","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0120","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0125","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0161-9","article-title":"Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0140","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"1","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0145","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0150","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","article-title":"A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process","volume":"148","author":"Barosi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/bs.ircmb.2021.09.001_bb0160","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"9464","key":"10.1016\/bs.ircmb.2021.09.001_bb0165","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2018.06.014","article-title":"Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms","volume":"71","author":"Berdeja","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0175","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","author":"Berk","year":"1986","journal-title":"Semin. Hematol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0180","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0185","first-page":"1","article-title":"Interferon alpha therapy in essential thrombocythemia and polycythemia vera\u2014a systematic review and meta-analysis","author":"Bewersdorf","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0190","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00277-018-3402-x","article-title":"The co-occurrence of driver mutations in chronic myeloproliferative neoplasms","volume":"97","author":"Boddu","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0200","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1080\/13543784.2016.1250882","article-title":"Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms","volume":"25","author":"Bose","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0205","first-page":"255","article-title":"Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia","volume":"130","author":"Bose","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood.2019002561","article-title":"Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning","volume":"135","author":"Bridgford","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0215","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","article-title":"Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients","volume":"25","author":"Caramazza","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0230","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"issue":"13","key":"10.1016\/bs.ircmb.2021.09.001_bb0235","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0245","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0255","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14740338.2021.1865912","article-title":"The safety of jak kinase inhibitors for the treatment of myelofibrosis","volume":"20","author":"Coltro","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.001_bb0260","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.001_bb0265","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0270","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0275","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2006.04.067","article-title":"Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density","volume":"55","author":"Davis","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0280","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"De Stefano","year":"2010","journal-title":"Intern. Emerg. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0285","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1538-7836.2007.02424.x","article-title":"Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders","volume":"5","author":"De Stefano","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0290","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.2019002614","article-title":"Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study","volume":"135","author":"De Stefano","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0295","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/leu.2015.271","article-title":"Oncogenic activation of MPL\/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms","volume":"30","author":"Defour","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2014.03.040","article-title":"Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases","volume":"134","author":"Dentali","year":"2014","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0305","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0310","series-title":"Cytokine Profile Changes In 309 Myelofibrosis Patients: Comparison Of JAK1\/JAK2 Inhibitor Therapy Vs. Placebo\u2013Correlative Analysis From The Comfort-I Trial","author":"Dueck","year":"2013"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0320","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.209965","article-title":"Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis","volume":"104","author":"Durrant","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0325","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"issue":"33","key":"10.1016\/bs.ircmb.2021.09.001_bb0330","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0335","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0340","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)","volume":"35","author":"Ferro","year":"2004","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0345","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of G ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0350","first-page":"1648","article-title":"A long-term safety and efficacy study of givinostat in patients with polycythemia vera: The first 4 years of treatment","volume":"130","author":"Finazzi","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.001_bb0355","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/bs.ircmb.2021.09.001_bb0360","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0365","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/bs.ircmb.2021.09.001_bb0370","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0375","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia","author":"Gerds","year":"2019"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0380","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0385","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0390","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria","volume":"30","author":"Gisslinger","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0395","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0400","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"FASEB J."},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.001_bb0405","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0410","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/bs.ircmb.2021.09.001_bb0415","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0420","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0425","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0430","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0435","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1002\/ajh.25668","article-title":"Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0440","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0445","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0450","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0455","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0460","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.001_bb0465","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0470","first-page":"4197","article-title":"Case series of potential Wernicke's encephalopathy in patients treated with Fedratinib","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0475","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0480","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0485","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0490","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0495","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease","volume":"8","author":"How","year":"2017","journal-title":"Ther. Adv. Hematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0500","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0505","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","article-title":"Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level","volume":"83","author":"Huang","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"20","key":"10.1016\/bs.ircmb.2021.09.001_bb0510","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0515","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann. Intern. Med."},{"issue":"7037","key":"10.1016\/bs.ircmb.2021.09.001_bb0520","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0525","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2NF-E2 mutations in MPN","volume":"210","author":"Jutzi","year":"2013","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0530","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0535","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2018-05-850339","article-title":"PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells","volume":"132","author":"Kahn","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0540","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0545","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a multi-center Bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0550","first-page":"1101","article-title":"Imetelstat treatment results in clinical benefits, including improved overall survival, in patients with higher-risk triple-negative myelofibrosis relapsed\/refractory to janus kinase inhibitors (jaki)","volume":"4","author":"Kiladjian","year":"2020","journal-title":"Hemasphere."},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.001_bb0555","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0560","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.001_bb0565","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0570","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-137285","article-title":"PTG-300 eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera patients","author":"Kremyanskaya","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0575","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0580","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0585","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/leu.2017.230","article-title":"Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status","volume":"32","author":"Kubesova","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0590","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/archinte.1989.00390010109013","article-title":"Erythromelalgia and myeloproliferative disorders","volume":"149","author":"Kurzrock","year":"1989","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0595","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0600","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.25335","article-title":"Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0605","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0610","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0615","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41375-020-0909-7","article-title":"Risk of infections in patients with myeloproliferative neoplasms\u2014a population-based cohort study of 8363 patients","volume":"35","author":"Landtblom","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0620","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1179\/102453309X12473408860587","article-title":"Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission","volume":"14","author":"Larsen","year":"2009","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0625","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Larsen","year":"2013","journal-title":"Leuk. Res."},{"issue":"20","key":"10.1016\/bs.ircmb.2021.09.001_bb0630","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0635","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0640","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24437","article-title":"Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms","volume":"91","author":"Loscocco","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"52","key":"10.1016\/bs.ircmb.2021.09.001_bb0650","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0655","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1074\/jbc.M707125200","article-title":"Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F","volume":"283","author":"Lu","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0660","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2013-11-536854","article-title":"The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon \u03b1 2a target JAK2V617F-positive progenitor and stem cells","volume":"124","author":"Lu","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0665","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: A systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.001_bb0670","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/bloodadvances.2019000646","article-title":"Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients","volume":"3","author":"Maffioli","year":"2019","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0675","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.1979.tb03740.x","article-title":"The reticulin content of bone marrow in acute leukaemia in adults","volume":"43","author":"Manoharan","year":"1979","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0680","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN)","author":"Marcault","year":"2021","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0685","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0690","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V9.4.321.321","article-title":"Erythroleukemia, with special emphasis on the acute or incomplete variety: Report of five cases","volume":"9","author":"Martin","year":"1954","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0695","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1002\/ajh.23809","article-title":"Cerebral vein thrombosis in patients with P hiladelphia-negative myeloproliferative neoplasms An E uropean L eukemia N et study","volume":"89","author":"Martinelli","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0700","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","volume":"89","author":"Mart\u00ednez-Trillos","year":"2010","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30030-3","article-title":"Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up","volume":"4","author":"Masarova","year":"2017","journal-title":"Lancet Haematol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0710","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127119","article-title":"MANIFEST, a phase 2 study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), as monotherapy or \u201cadd-on\u201d to ruxolitinib, in patients with refractory or intolerant advanced myelofibrosis","author":"Mascarenhas","year":"2019"},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0715","first-page":"254","article-title":"Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia","volume":"130","author":"Mascarenhas","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0720","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0725","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-99-111946","volume":"132","author":"Mascarenhas","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0730","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0735","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients: update of MANIFEST phase 2 study","author":"Mascarenhas","year":"2020"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0740","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-140830","article-title":"Rationale for and results of a phase I study of the TGF-beta 1\/3 inhibitor AVID200 in subjects with myelofibrosis: MPN-RC 118 trial","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0745","first-page":"1107","article-title":"Favorable overall survival with imetelstat treatment correlates with other clinical benefits in intermediate 2 or high risk myelofibrosis relapsed\/refractory to janus kinase inhibitor","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Hemasphere."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0750","first-page":"1098","article-title":"Telomerase activity, telomere length and HTERT expression correlate with clinical outcomes in higher-risk myelofibrosis (MF) relapsed\/refractory (R\/R) to janus kinase inhibitor treated with imetelstat","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Hemasphere."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0755","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0760","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0765","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41375-019-0564-z","article-title":"Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface","volume":"34","author":"Masubuchi","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0770","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) An international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0775","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0780","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0785","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.6004\/jnccn.2016.0169","article-title":"Myeloproliferative neoplasms, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"14","author":"Mesa","year":"2016","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0790","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ejh.12707","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","volume":"97","author":"Mesa","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"34","key":"10.1016\/bs.ircmb.2021.09.001_bb0795","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor\u2013na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0800","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"issue":"Supplement 1","key":"10.1016\/bs.ircmb.2021.09.001_bb0805","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2018-99-111929","volume":"132","author":"Mesa","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0810","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1080\/09537100600758677","volume":"17","author":"Michiels","year":"2006","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb0815","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Milosevic Feenstra","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0820","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0825","first-page":"1194","article-title":"Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis","volume":"89","author":"Mossuz","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0830","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the E uropean U nion","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.001_bb0835","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb0840","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0845","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0850","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0855","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0860","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0865","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0870","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0875","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0880","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0885","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb0890","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0895","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb0900","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1538-7836.2012.04719.x","article-title":"The JAK2 V617F mutation in patients with cerebral venous thrombosis","volume":"10","author":"Passamonti","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb0905","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1038\/leu.2017.169","article-title":"A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis","volume":"31","author":"Passamonti","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0910","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.001_bb0915","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1182\/blood-2018-09-874578","article-title":"Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants","volume":"133","author":"Pecquet","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.001_bb0920","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/blood-2019-01-897637","article-title":"Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy","volume":"133","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0925","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136938","article-title":"The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed\/refractory myelofibrosis","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/bs.ircmb.2021.09.001_bb0930","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb0935","first-page":"23","article-title":"Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy","volume":"1","author":"Piasecki","year":"2020","journal-title":"Arch. Stem Cell Ther."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb0940","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0945","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0955","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","article-title":"Inhibition of fibrocyte differentiation by serum amyloid P","volume":"171","author":"Pilling","year":"2003","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb0960","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","article-title":"Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy","volume":"132","author":"Porpaczy","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb0965","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp. Hematol."},{"issue":"32","key":"10.1016\/bs.ircmb.2021.09.001_bb0970","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb0975","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb0980","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/bs.ircmb.2021.09.001_bb0985","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb0990","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"Rocca","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb0995","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1000","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.exphem.2013.03.007","article-title":"Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy","volume":"41","author":"Ruella","year":"2013","journal-title":"Exp. Hematol."},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.001_bb1005","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Rumi","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb1010","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2016-04-711150","article-title":"LNK mutations in familial myeloproliferative neoplasms","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1020","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25489","article-title":"Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms","volume":"94","author":"Rumi","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"7257","key":"10.1016\/bs.ircmb.2021.09.001_bb1030","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1035","series-title":"Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution","author":"S\u00e1nchez Luceros","year":"2002"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.001_bb1040","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2 V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb1045","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases","volume":"95","author":"Sant'Antonio","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb1050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb1055","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1060","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb1065","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1070","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2017-07-746453","article-title":"Age-related clonal hematopoiesis","volume":"131","author":"Shlush","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/bs.ircmb.2021.09.001_bb1075","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2015-01-621110","article-title":"Molecular insights into regulation of JAK2 in myeloproliferative neoplasms","volume":"125","author":"Silvennoinen","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/cncr.22026","article-title":"Long-term effects of the treatment of polycythemia vera with recombinant interferon-\u03b1","volume":"107","author":"Silver","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1090","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/ijms19030898","article-title":"Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1095","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1100","series-title":"The Pan-JAK inhibitor Ruxolitinib impairs T-cell activation, cytokine production and proliferation in vivo and in vitro","author":"Stuebig","year":"2013"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ajh.23409","article-title":"The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms","volume":"88","author":"Tadmor","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2141.2012.09249.x","article-title":"Guidelines on the investigation and management of venous thrombosis at unusual sites","volume":"159","author":"Tait","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1115","first-page":"1091","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory\/intolerant to JAK inhibitor: Update from phase 2 MANIFEST study","volume":"4","author":"Talpaz","year":"2020","journal-title":"Hemasphere."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0347-1","article-title":"Primary erythromelalgia: a review","volume":"10","author":"Tang","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2017.06.002","article-title":"Genetic risk assessment in myeloproliferative neoplasms","author":"Tefferi","year":"2017"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb1135","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/bs.ircmb.2021.09.001_bb1140","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1145","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1150","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.001_bb1155","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb1160","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb1165","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb1170","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1175","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb1180","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.001_bb1185","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1190","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1195","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/leu.2017.318","article-title":"Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb1200","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/bjh.15010","article-title":"Screening for ASXL 1 and SRSF 2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb1205","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1002\/ajh.25017","article-title":"JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1215","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.001_bb1220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1225","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/JPR.S154462","article-title":"Current pain management strategies for patients with erythromelalgia: a critical review","volume":"11","author":"Tham","year":"2018","journal-title":"J. Pain Res."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb1230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","article-title":"Grade of bone marrow fibrosis is associated with relevant hematological findings\u2014a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2006","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb1235","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01013883","article-title":"Ultrastructure of chronic megakaryocytic-granulocytic myelosis","volume":"32","author":"Thiele","year":"1976","journal-title":"Blut"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.001_bb1240","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica."},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.001_bb1245","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-5-2","article-title":"Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis","volume":"5","author":"Tognon","year":"2012","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb1255","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/ejh.13048","article-title":"Associations between fatigue, physical activity, and QoL in patients with myeloproliferative neoplasms","volume":"100","author":"Tolstrup Larsen","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb1260","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","article-title":"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways","volume":"105","author":"Tong","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1265","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2019.1688323","article-title":"Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis","volume":"61","author":"Tremblay","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.001_bb1270","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1275","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/asheducation-2007.1.363","article-title":"Thrombocytosis and thrombosis","volume":"2007","author":"Vannucchi","year":"2007","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb1280","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1285","first-page":"171","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther. Adv. Hematol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb1295","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1300","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1305","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p. V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann. Hematol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.001_bb1310","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.001_bb1315","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1320","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2018-99-116474","article-title":"AVID200, a potent trap for TGF-\u03b2 ligands inhibits TGF-\u03b21 signaling in human myelofibrosis","volume":"132","author":"Varricchio","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.001_bb1325","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.001_bb1330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.001_bb1335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2017.05.002","article-title":"A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia","volume":"60","author":"Verstovsek","year":"2017","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1345","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.001_bb1350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2017.08.010","article-title":"A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia","volume":"61","author":"Verstovsek","year":"2017","journal-title":"Leuk. Res."},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.001_bb1360","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2017-02-765032","article-title":"Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results","volume":"130","author":"Verstovsek","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/bs.ircmb.2021.09.001_bb1365","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/bs.ircmb.2021.09.001_bb1370","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"S828 A Randomized, Double Blind Phase 2 Study of 3 Different Doses of PRM-151 in Patients with Myelofibrosis who Were Previously Treated with or Ineligible for Ruxolitinib","volume":"3","author":"Verstovsek","year":"2019","journal-title":"Hemasphere."},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1375","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140820","article-title":"Real-world survival among patients with intermediate-to high-risk myelofibrosis in the United States: impact of ruxolitinib approval","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/bs.ircmb.2021.09.001_bb1380","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/bloodadvances.2018022012","article-title":"Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.001_bb1385","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/bs.ircmb.2021.09.001_bb1390","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1395","article-title":"A Phase 2 Study of the LSD1 Inhibitor IMG7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis","author":"Yacoub","year":"2020"},{"key":"10.1016\/bs.ircmb.2021.09.001_bb1400","article-title":"Addition of parsaclisib, a PI3KDELTA inhibitor, in patients (PTS) with suboptimal response to ruxolitinib (RUX): a phase 2 STUDY in PTS with myelofibrosis (MF)","author":"Yacoub","year":"2020"},{"issue":"7367","key":"10.1016\/bs.ircmb.2021.09.001_bb1405","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.001_bb1410","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3109\/10428194.2015.1015124","article-title":"Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis","volume":"56","author":"Zamora","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"19","key":"10.1016\/bs.ircmb.2021.09.001_bb1415","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","article-title":"Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.001_bb1420","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:10:13Z","timestamp":1753787413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323899390"],"references-count":282,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.09.001","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}